Zobrazeno 1 - 10
of 47
pro vyhledávání: '"ANDERS L. CARLSON"'
Publikováno v:
Case Reports in Endocrinology, Vol 2013 (2013)
Incidentally discovered adrenal masses (incidentalomas) are common and present challenges both in diagnosis and management. When incidentally discovered adrenal masses are bilateral, a refined diagnostic approach is warranted since bilateral disease
Externí odkaz:
https://doaj.org/article/c7d700c0ea8d4be8a24d1351b7df7b63
Autor:
Mary Johnson, Richard M Bergenstal, Roy W Beck, Anders L Carlson, Zoey Li, Elizabeth Norton, Sean Dunnigan, Matthew Banfield, Katie J Krumwiede, Judy R Sibayan, Peter Calhoun, Celeste Durnwald
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 12, Iss 3 (2024)
Introduction To characterize glucose levels during uncomplicated pregnancies, defined as pregnancy with a hemoglobin A1c 120 mg/dL (6.7 mmol/L) was 11%, and median per cent time >140 mg/dL (7.8 mmol/L) was 2.5%. Mean post-prandial peak glucose was 12
Externí odkaz:
https://doaj.org/article/b9e14acf68e64e6ab183bf0af5fd5097
Autor:
Esra Karslioglu French, Tom Elliott, Anders L Carlson, Timothy Dilon Daniel, Andrea DeSantis, Serge Jabbour, Davida Kruger, Eden Miller, Kerem Ozer
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/8d1670f73f3648d4a505f452bf2a9428
Autor:
Georgia M. Davis, Anne L. Peters, Bruce W. Bode, Anders L. Carlson, Bonnie Dumais, Todd E. Vienneau, Lauren M. Huyett, Trang T. Ly
Publikováno v:
Diabetes Care. 46:742-750
OBJECTIVEAutomated insulin delivery (AID) has rarely been studied in adults with type 2 diabetes. We tested the feasibility of using AID for type 2 diabetes with the Omnipod 5 System in a multicenter outpatient trial.RESEARCH DESIGN AND METHODSPartic
Autor:
Satish K, Garg, George, Grunberger, Ruth, Weinstock, Margaret L, Lawson, Irl B, Hirsch, Linda A, DiMeglio, Rodica, Pop-Busui, Athena, Philis-Tsimikas, Mark, Kipnes, David R, Liljenquist, Ronald L, Brazg, Yogish C, Kudva, Bruce A, Buckingham, Janet B, McGill, Anders L, Carlson, Amy B, Criego, Mark P, Christiansen, Kevin B, Kaiserman, Kurt J, Griffin, Greg P, Forlenza, Bruce W, Bode, Robert H, Slover, Ashleigh, Keiter, Chenxiao, Ling, Briggitte, Marinos, Toni L, Cordero, John, Shin, Scott W, Lee, Andrew S, Rhinehart, Robert A, Vigersky, Mary, Jane Clifton
Publikováno v:
Diabetes Technology & Therapeutics. 25:1-12
Publikováno v:
Clinical Diabetes. 40:413-424
Fast-acting insulin aspart (faster aspart) is an ultra-rapid-acting formulation of insulin aspart developed to more closely match the prandial endogenous insulin profile, and its accelerated absorption kinetics are expected to provide clinical benefi
Autor:
Richard A.M. Jonkers, Robert A. Vigersky, John H. Shin, Toni L. Cordero, Anirban Roy, Dorothy I. Shulman, Rodica Pop-Busui, Melissa Vella, Athena Philis-Tsimikas, Mark Kipnes, Benyamin Grosman, John C. Reed, Xiaoxiao Chen, Andrew S. Rhinehart, Kevin B. Kaiserman, Mark P. Christiansen, Anders L. Carlson, James Thrasher, Bruce W. Bode, Robert H. Slover, Jennifer L. Sherr, Scott W. Lee, Ron Brazg, Satish K. Garg, David R. Lilenquist
Publikováno v:
Diabetes Technology & Therapeutics. 24:178-189
Introduction: This trial assessed safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal (Auto Basal) and automated bolus correction (Auto Correction) in adol...
Autor:
Gregory P. Forlenza, Carol J. Levy, Rodolfo J. Galindo, Janet B. McGill, Guillermo E. Umpierrez, Anders L. Carlson, Christopher G. Parkin, Grazia Aleppo, Davida F. Kruger
Publikováno v:
Diabetes Technology & Therapeutics
Numerous studies have demonstrated the clinical value and safety of insulin pump therapy in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for insulin pump coverage required by the Centers for Medicare & Medicaid S
Autor:
Christopher G. Parkin, Guillermo E. Umpierrez, Carol J. Levy, Grazia Aleppo, Davida F. Kruger, Janet B. McGill, Rodolfo J. Galindo, Anders L. Carlson
Publikováno v:
Diabetes Technology & Therapeutics
Numerous studies have demonstrated the clinical value of continuous glucose monitoring (CGM) in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for CGM coverage required by the Centers for Medicare & Medicaid Servic
Autor:
Amy Criego, Sarah A. Macleish, Jennifer L. Sherr, Jordan E. Pinsker, Ruth S. Weinstock, Anders L. Carlson, Anuj Bhargava, Richard M. Bergenstal, Thomas C. Jones, Daniel J. DeSalvo, Grazia Aleppo, Carol J. Levy, Bruce W. Bode, Sanjeev N. Mehta, Gregory P. Forlenza, Viral N. Shah, Bruce A. Buckingham, Irl B. Hirsch, David W Hansen, Sue A. Brown, Lori M. Laffel, Trang T. Ly
Publikováno v:
Diabetes Care
OBJECTIVE Advances in diabetes technology have transformed the treatment paradigm for type 1 diabetes, yet the burden of disease is significant. We report on a pivotal safety study of the first tubeless, on-body automated insulin delivery system with